Fig. 6: Effect of G2/M arrest inhibitors on tumor progression.

a Athymic mice bearing Ramos cell xenografts received (i) one intravenous injection of ¹⁷⁷Lu-lilotomab (250 MBq/kg or 500 MBq/kg), (ii) 30 mg/kg MK-1775 (twice a day) for 5 days; (iii) one injection of ¹⁷⁷Lu-lilotomab (250 MBq/kg) + 30 mg/kg MK-1775 (twice a day) from day 1 to 5 post injection (n = 6–9/group). Tumor growth (left panel) was monitored as a function of time post xenograft, and Kaplan–Meyer survival curves were established (right panel). b Athymic mice bearing OCI-Ly8 cell xenografts received (i) one intravenous injection of ¹⁷⁷Lu-lilotomab (250 MBq/kg or 500 MBq/kg), (ii) 30 mg/kg MK-1775 (twice a day) for 5 days, (iii) one injection of ¹⁷⁷Lu-lilotomab (250 MBq/kg) + 30 mg/kg MK-1775 (twice a day) from day 1 to 5 post injection, (iv) unlabeled mAbs (2.5 mg/kg) (n = 6–8/group). Tumor growth (left panel) was monitored as a function of time post xenograft, and Kaplan–Meyer survival curves were established (right panel). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 (compared with the NT/NaCl-treated group).